Immunology and Microbiology
Adalimumab
100%
Ustekinumab
87%
COVID-19
50%
Influenza
50%
Interferon Type I
50%
Transcriptomics
50%
Oxidative Stress
50%
Peptides
50%
HLA-DR
50%
Influenza Vaccine
50%
Immunogenicity
50%
Drug Antibody
50%
Allele
37%
Psoriatic Arthritis
25%
Biological Product
22%
ELISA
20%
Major Histocompatibility Complex
20%
Radioimmunoassay
15%
Gene Expression
13%
Gene Interaction
12%
Genetic Susceptibility
12%
Vaccine Efficacy
10%
Host Immune Response
10%
TNF Inhibitor
10%
Tryptophan
10%
Lysine
10%
Cell-Based Vaccine
5%
Spike
5%
Drug Exposure
5%
Muscle
5%
Anaphylaxis
5%
Immune Response
5%
Antibody Response
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Hemagglutination Inhibition
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Ustekinumab
100%
Drug Antibody
58%
Inflammation
50%
Seasonal Influenza
50%
Pharmacokinetic
50%
Influenza Vaccine
50%
Pharmacodynamics
50%
Live Attenuated Influenza Vaccine
50%
Interferon
50%
COVID-19 Vaccine
50%
Placebo
50%
Immunogenicity
50%
Adverse Event
30%
Enzyme-Linked Immunosorbent Assay
20%
Radioimmunoassay
15%
Vaccine Efficacy
10%
EC50
8%
Inflammatory Disease
8%
Mixture Model
8%
Therapeutic Drug Monitoring
8%
Monotherapy
8%
Skin Defect
8%
SARS Coronavirus
5%
Table Salt
5%
Anaphylaxis
5%
Intramuscular Injection
5%
Myalgia
5%
Medicine and Dentistry
Placebo
50%
Treatment Response
50%
Psoriasis
50%
Seasonal Influenza
50%
Influenza Vaccine
50%
COVID-19 Vaccine
50%
Biological Marker
50%
Immunogenicity
50%
Adalimumab
33%
Adverse Event
30%
Allele
25%
Odds Ratio
25%
Ustekinumab
25%
Reactogenicity
20%
Psoriatic Arthritis
16%
COVID-19
10%
Vaccine Efficacy
10%
Genetic Susceptibility
8%
Gene Interaction
8%
Cost-Effectiveness Analysis
8%
Biological Product
8%
Observational Study
8%
Psoriasis Area and Severity Index
8%
Injection Site
5%
Antibody Response
5%
Anaphylaxis
5%
Myalgia
5%
Hemagglutination Inhibition
5%
Immune Response
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Table Salt
5%
Contraindication
5%
Intramuscular Injection
5%
